Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination ...
Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United StatesVANCOUVER, ...
After his colon cancer returned in full force, Marine Corps veteran Joe Worthy decided to help other veterans, advocating for ...
Zacks Investment Research on MSN
INBX stock up on upbeat clinical update from colorectal cancer study
Shares of Inhibrx Biosciences INBX rallied 36.9% on Wednesday. The massive surge was triggered by encouraging updated interim ...
PDS01ADC is a tumor-targeted IL-12 immunocytokine designed to activate the immune system directly within the tumor ...
Preliminary results of fruquintinib in combination with FOLFIRI as second-line treatment for RAS-mutant metastatic colorectal cancer: A prospective, single-center phase 2 study. Efficacy and safety of ...
Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35% Trials ...
CLEVELAND, Ohio — The benefits of getting regular exercise, combining two cancer drugs with chemotherapy, and using AI to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results